Stay updated on Volitinib for Primary CNS Tumors Clinical Trial

Sign up to get notified when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Volitinib for Primary CNS Tumors Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T22:42:46.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    This change removes links and files for critical study documents from the record, including consent forms and the protocol; the study page will have fewer references to its foundational materials and procedures.
    Difference
    23%
    Check dated 2026-09-22T23:47:10.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.7.0, replacing the previous v3.6.6, signaling a routine platform update rather than a modification to the study details.
    Difference
    0.0%
    Check dated 2026-09-16T00:09:15.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Revision: v3.6.6 replaces v3.6.5 on the page, indicating a new build of the site's framework or styling. This update appears to be a backend/software change with no visible changes to the study information.
    Difference
    0.0%
    Check dated 2026-09-01T19:26:17.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page revision identifier was updated from v3.6.4 to v3.6.5, indicating a new version of the page. This appears to be a maintenance/metadata update rather than a change to the study content.
    Difference
    0.0%
    Check dated 2026-08-11T08:23:29.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    A new Phase I Savolitinib study title is added, expanding the scope to MET-activated CNS tumors and listing related drug names (Orpathys, HMPL504, AZD-6094). Minor eligibility wording changes (serum creatinine) and procedural updates (e.g., Sample Collection) are also reflected.
    Difference
    0.6%
    Check dated 2026-08-04T06:37:42.000Z thumbnail image

Stay in the know with updates to Volitinib for Primary CNS Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Volitinib for Primary CNS Tumors Clinical Trial page.